Wire · opportunities
Organ transplant technology company hid that it forced product bundling on customers, (Jul 23, 2026)
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 24 July 2026 · Fusion42 review
TransMedics Group survived a motion to dismiss on securities fraud claims that it misrepresented forced bundling of its organ care system (OCS) with its National OCS Program (NOP) logistics service to hospitals. A Massachusetts federal court found plaintiffs adequately pleaded that the company's CEO made materially false statements denying forced bundling despite hospital witnesses testifying the practice was real.
This Wire brief sits within Fusion42's coverage of Digital Health.
◆ ◆ The Wire takeaway
If you sell hardware and services together to hospitals, document that customers actually want the bundle and aren't forced into it—this court just ruled that denying bundling allegations in public statements, when hospital staff say otherwise, is actionable fraud. Your next funding round or exit will turn on whether customers can testify your bundle was coercive.
◆ Coverage
1 source · 24 Jul 2026
◆ Related on Wire
◆ Topics